Popp Erik, Vogel Peter, Teschendorf Peter, Böttiger Bernd W
Department of Anaesthesiology, University of Heidelberg, Im Neuenheimer Feld 110, D-69120 Heidelberg, Germany.
Resuscitation. 2007 Jan;72(1):137-44. doi: 10.1016/j.resuscitation.2006.05.015. Epub 2006 Oct 27.
Vasopressors are recommended for cardiopulmonary resuscitation (CPR) after cardiac arrest. In order to assess possible benefits regarding neurological recovery, vasopressin versus adrenaline and the combination of both was tested against placebo in a cardiac arrest model in rats.
Under anaesthesia with halothane and N2O, cardiac arrest was initiated via transoesophageal electrical fibrillation. After 7 min of global ischaemia, CPR was performed by external chest compression combined with defibrillation. Animals were randomly assigned to three groups receiving adrenaline, vasopressin and a combination of both (n = 15 per group) versus placebo (n = 8). At 1, 3 and 7 days animals were tested according to a neurological deficit score (NDS). After 7 days of reperfusion, coronal brain sections were analysed by Nissl- and TUNEL-staining. Viable as well as TUNEL-positive neurons were counted in the hippocampal CA-1 sector. For statistical analysis, the log rank and the Kruskal-Wallis ANOVA test were used. All data are given as mean+/-S.D.; a p-value <0.05 was considered significant.
Mean arterial blood pressure (MAP) measured in the aorta did not differ between the vasopressor groups, whereas placebo animals had significantly lower levels. Survival to 7 days revealed significant differences between the placebo (n = 0/8) and all vasopressor groups (adrenaline, 10/15; adrenaline/vasopressin, 8/15; vasopressin, 12/15). Histological deficit scoring by quantitative analysis of the Nissl- and TUNEL-staining showed no difference in the amount of viable and apoptotic neurons in the vasopressin group (viable: 33+/-18; apoptotic: 63+/-23) versus the adrenaline group (viable: 21+/-12; apoptotic: 67+/-17) and the adrenaline/vasopressin group (viable: 31+/-26; apoptotic: 61+/-27). Neurological deficit scoring did not show any differences between the vasopressor groups.
Administration of arginine-vasopressin during CPR does not improve behavioural and cerebral histopathological outcome, compared to the use of adrenaline or the combination of both vasopressors, after cardiac arrest in rats.
血管加压药被推荐用于心脏骤停后的心肺复苏(CPR)。为了评估其对神经功能恢复可能带来的益处,在大鼠心脏骤停模型中,对血管加压素与肾上腺素以及两者联合使用与安慰剂进行了对比测试。
在氟烷和一氧化二氮麻醉下,通过经食管电除颤引发心脏骤停。全脑缺血7分钟后,通过胸外按压联合除颤进行心肺复苏。将动物随机分为三组,分别接受肾上腺素、血管加压素以及两者联合用药(每组n = 15),与安慰剂组(n = 8)进行对比。在第1、3和7天,根据神经功能缺损评分(NDS)对动物进行测试。再灌注7天后,对冠状脑切片进行尼氏染色和TUNEL染色分析。对海马CA-1区的存活神经元以及TUNEL阳性神经元进行计数。采用对数秩检验和Kruskal-Wallis方差分析进行统计学分析。所有数据均以平均值±标准差表示;p值<0.05被认为具有统计学意义。
血管加压药组之间在主动脉测量的平均动脉血压(MAP)无差异,而安慰剂组动物的MAP水平显著较低。存活至7天显示,安慰剂组(n = 0/8)与所有血管加压药组(肾上腺素组,10/15;肾上腺素/血管加压素组,8/15;血管加压素组,12/15)之间存在显著差异。通过对尼氏染色和TUNEL染色的定量分析进行组织学缺损评分显示,血管加压素组(存活:33±18;凋亡:63±23)与肾上腺素组(存活:21±12;凋亡:67±17)以及肾上腺素/血管加压素组(存活:31±26;凋亡:61±27)在存活神经元和凋亡神经元数量上无差异。神经功能缺损评分在血管加压药组之间未显示任何差异。
在大鼠心脏骤停后进行心肺复苏期间,与使用肾上腺素或两种血管加压药联合使用相比,给予精氨酸血管加压素并不能改善行为和脑组织病理学结果。